NeuroPace Inc (NPCE) PT Raised to $19 at Leerink Partners

Leerink Partners analyst Mike Kratky raised the price target on NeuroPace Inc (NASDAQ: NPCE) to $19.00 (from $18.00) while maintaining a Outperform rating.

The analyst comments "We liked what we saw from NPCE's 3Q results. We are increasing our PT to $19 from $18. Reiterate Outperform. Overall, we came away from NPCE's 3Q25 results with a renewed sense of optimism on the stock. We see multiple potential avenues for upside from here coming from the company's core commercial business in focal DRE and from potential indication expansion in IGE and other populations. First, NPCE delivered another strong topline beat (+13% vs. cons.) led by RNS, with gross margin of 77.4% materially above consensus of 72.6%. Second, we were very pleased by management's decision to start providing additional reporting disclosures moving forward, including revenue by line-item. This will create significantly more visibility on the company's underlying RNS sales growth in focal drug-resistant epilepsy (DRE). In our view, this signals management's confidence in their core RNS business and should also lead to better predictability for NPCE investors moving forward. To that point, we believe NPCE has set a relatively comfortable bar with its implied 4Q revenue and gross margin guidance that should create additional upside opportunities for the stock on a near-term basis. Lastly, we remain encouraged by management's continued confidence on their potential regulatory path forward in IGE following their most recent pre-submission meeting with the FDA, with their submission still on track for YE25. With those factors in mind, we believe NPCE's 3Q earnings were definitively more positive than preliminary headlines and corresponding estimate revisions might otherwise suggest."

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
• SeaStar Medical (ICU) Misses Q1 EPS by 4c